These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 16105846

  • 1. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?
    van de Wal RM, van Veldhuisen DJ, van Gilst WH, Voors AA.
    Eur Heart J; 2005 Nov; 26(22):2361-7. PubMed ID: 16105846
    [Abstract] [Full Text] [Related]

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 3. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ, Smith SM, Choksi R.
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A, Divchev D, Luchtefeld M, Schieffer B.
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 6. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 7. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A, Battegay E.
    Praxis (Bern 1994); 2005 Apr 13; 94(15):581-94. PubMed ID: 15884724
    [Abstract] [Full Text] [Related]

  • 8. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP.
    Cardiol Rev; 2006 Apr 13; 14(2):81-7. PubMed ID: 16493245
    [Abstract] [Full Text] [Related]

  • 9. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul 13; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 10. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure.
    Carson PE.
    Am Heart J; 2000 Sep 13; 140(3):361-6. PubMed ID: 10966531
    [Abstract] [Full Text] [Related]

  • 11. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ.
    Prev Cardiol; 2008 Sep 13; 11(4):215-22. PubMed ID: 19476574
    [Abstract] [Full Text] [Related]

  • 12. [Blockade of the renin-angiotensin system by a combination of ACE inhibitors and AT1 receptor antagonists].
    Azizi M.
    Rev Prat; 2004 Jun 15; 54(11):1167-74. PubMed ID: 15496022
    [Abstract] [Full Text] [Related]

  • 13. Have angiotensin receptor blockers lived up to expectations?
    Fitchett D.
    Can J Cardiol; 2005 May 15; 21(7):569-75. PubMed ID: 15940354
    [Abstract] [Full Text] [Related]

  • 14. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan 15; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 15. Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy.
    Cohn JN, Goldman JM.
    Am J Hypertens; 2008 Mar 15; 21(3):248-56. PubMed ID: 18219303
    [Abstract] [Full Text] [Related]

  • 16. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH, Lyoussi B, Hernández-Hernández R, Velasco M.
    Am J Ther; 2007 Mar 15; 14(4):386-402. PubMed ID: 17667215
    [Abstract] [Full Text] [Related]

  • 17. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA, Movahed A.
    Rev Cardiovasc Med; 2005 Mar 15; 6(4):206-13. PubMed ID: 16379016
    [Abstract] [Full Text] [Related]

  • 18. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA.
    Am J Cardiol; 2007 Aug 06; 100(3A):45J-52J. PubMed ID: 17666198
    [Abstract] [Full Text] [Related]

  • 19. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II).
    Jacobsen PK.
    J Renin Angiotensin Aldosterone Syst; 2005 Sep 06; 6(2):55-68. PubMed ID: 16470484
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED, Preddie DC.
    Ethn Dis; 2002 Sep 06; 12(4):S3-49-52. PubMed ID: 12477155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.